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Sir: Cervical cancer is the second most common
malignancy in women worldwide. In developing coun-
tries, most cases are still diagnosed with locally
advanced disease, so the great challenge in the
management of advanced cervical cancer remains
the control and prevention of distant metastasis. A
prominent feature of clinically advanced cervical can-
cers is hypoxia
1,2 which is, therefore, a therapeutic and
prognostic factor associated with radio-resistance and
worsened clinical outcome.
3–5 A central coordinator of
the hypoxic cellular response is hypoxia-inducible
factor-1a (HIF-1a), a master transcription factor reg-
ulating the expression of numerous downstream tar-
gets.
6,7 HIF-1a binding to hypoxia response elements at
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Figure 1. Immunohistochemical detection of human growth and transformation-dependent protein (HGTD-P) in cervical cancer (A, B), normal
mucosa (C) and precancerous lesions (E–H). Representative samples of cervical cancer in which HGTD-P shows diffuse and strong staining in the
cytoplasm of tumour cells (A), and no staining in tumour cells (B). C, Normal exocervical mucosa did not express HGTD-P. Among precancerous
lesions including koilocytosis (E), cervical intraepithelial neoplasia (CIN)1 (F), CIN2 (G), CIN3 (H), HGTD-P expression was conﬁned to dysplastic
cells of the individual lesions. A representative case in which various cervical lesions are included within a microscopic ﬁeld shows strong positive
staining in cancer (c), less strong positive in CIN3 (ci) and no staining in normal cervical samples (n).
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Histopathology 2010, 57, 479–497enhancers of target genes increases the expression of
molecules which regulate angiogenesis, glucose trans-
port, glycolysis, tissue invasion ⁄ metastasis and cell
proliferation.
6 Recently, we reported the identiﬁcation
of human growth and transformation-dependent
protein (HGTD-P) as a new HIF-1a-responsive protein.
8
Although the majority of genes downstream of HIF-1a
participate in survival signalling pathways against
Table 1. Comparison of human growth and transformation-
dependent protein (HGTD-P) expression in cervical cancer
and precancerous lesions
HGTD-P
expression CIN1 CIN2 CIN3
Cervical
cancer Total
Negative 8 (66.7) 5 (71.4) 7 (53.8) 25 (29.4) 45
Positive 4 (33.3) 2 (28.6) 6 (46.2) 60 (70.6) 72
Total 12 7 13 85 117
CIN, cervical intraepithelial neoplasia.
P = 0.009, analysed by Pearson’s chi-square test.
Table 2. Comparison of human growth and transformation-
dependent protein (HGTD-P) expression with hypoxia-
inducible factor-1a (HIF-1a) expression in uterine cervical
cancer
HGTD-P expression
HIF-1a expression (%)
Negative Positive Total
Negative 5 (83.3) 2 (22.2) 7
Positive 1 (16.7) 7 (77.8) 8
P = 0.042, analysed by Fisher’s exact test.
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Figure 2. Immunohistochemistry of hypoxia-inducible factor-1a (HIF-1a)( A, C) and human growth and transformation-dependent protein
(HGTD-P) (B, D) in identical tumour samples. A, B, Tumour cells strongly expressed both HIF-1 and HGTD-P. C, D, The tumour expressed neither
HIF-1a nor HGTD-P.
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metabolic demands for adaptation to hypoxic condi-
tions,
9–11 little is known about the role of HGTD-P
during carcinogenesis.
We investigated the expression of HGTD-P in human
tissue samples of uterine cervical cancer (UCC; n = 85)
and normal cervical tissue (n = 20) using immunohis-
tochemistry with rabbit anti-HGTD-P antibody.
12 As
shown in Figure 1A, HGTD-P was stained strongly in
the cytoplasm of the tumour cells, but no staining was
observed in the nucleus or cytoplasmic membrane,
whereas normal cervical mucosa showed no staining at
all (Figure 1C). Most UCC tissues (70.6%) were positive
for HGTD-P. Next, we aimed to determine the timing of
aberrant HGTD-P expression during multistep cervical
carcinogenesis and performed immunohistochemistry
in cervical precancerous lesions, including cervical
intraepithelial neoplasia (CIN)1 (n = 12), CIN2 (n =7 )
and CIN3 (n = 13). As a result, fewer than half the
precancerous lesions were stained moderately with
HGTD-P, which was conﬁned to dysplastic cells (Fig-
ure 1E–H). In fact, 33.3% of CIN1, 28.6% of CIN2 and
46.2% of CIN3 expressed cytoplasmic HGTD-P,
whereas 70.6% of UCC was positive for HGTD-P
(Table 1). The cases in which UCC tissue samples
included normal cervical mucosa and precancerous
lesions on a slide demonstrated diverse patterns of
HGTD-P expression that were dependent upon the type
of cervical lesion (Figure 1D). For example, HGTD-P
was stained strongly in UCC and moderately in CIN3,
whereas normal mucosa showed no staining. These
results suggest that HGTD-P expression is a common
and cancer-speciﬁc event in the uterine cervix, occur-
ring at an early stage of cervical carcinogenesis.
To determine the association between HGTD-P and
HIF-1a in human clinical samples, we performed
immunohistochemistry for HIF-1a in UCC tissues
(n = 15) and compared the result of HIF-1a staining
to that of HGTD-P expression. As a result, HIF-1a
overexpression was detected in 60% of UCC tissues;
77.8% of HIF-1a-overexpressed tumours also expressed
HGTD-P. The correlation of expression between these
two proteins was statistically signiﬁcant (Table 2;
P = 0.04). Representative cases of UCC with positive
correlation between the two proteins are shown in
Figure 2. This ﬁnding suggests that HGTD-P partici-
pates in a molecular mechanism of hypoxia-regulated
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Figure 3. Overall survival curves in patients with uterine cervical
cancer depending upon human growth and transformation-depen-
dent protein (HGTD-P) expression. The patients with HGTD-P-
expressing tumours tend to have poor overall survival rate, compared
to those with tumours that do not express HGTD-P.
Table 3. Correlation of human growth and transformation-
dependent protein (HGTD-P) expression in uterine cervical
cancer with clinicopathological factors
Factors No.
HGTD-P expression
P-value* )(n = 25) +(n = 60)
Age (years)
£45 35 11 24 0.733
>45 50 14 36
Histological type
Squamous cell
carcinoma
63 16 47 0.355
Adenocarcinoma 15 7 8
Others 7 2 5
FIGO stage
IA1-IB1 61 21 40 0.122
IB2-IIIB 24 4 20
LN metastasis
No 71 20 51 0.760
Yes 12 4 8
Parametrial invasion
No 24 24 47 0.056
Yes 1 1 13
Death
No 75
Yes 10
FIGO, International Federation of Gynecology and Obstet-
rics; LN, lymph node.
*Fisher’s exact test.
Correspondence 481
  2010 Blackwell Publishing Ltd, Histopathology, 57, 479–497.tumour development in association with HIF-1a, and
furthermore is of great value for future investigation
regarding its role in cervical carcinogenesis.
Next, we determined any clinicopathological signif-
icance of the aberrant expression of HGTD-P in UCC
and compared HGTD-P-positive tumours to -negative
tumours in relation to clinicopathological parameters.
HGTD-P-positive-tumours tend to be associated with
advanced International Federation of Gynecology and
Obstetrics (FIGO) stage, parametrial invasion and
tumour recurrence, but this association did not reach
statistical signiﬁcance (Table 3). The overall survival
rate was poorer in patients with HGTD-P expression
than in those without HGTD-P expression (Figure 3).
However, this difference did not reach statistical
signiﬁcance (P = 0.272).
In summary, we have shown that HGTD-P expres-
sion is a frequent event in UCC and is associated
signiﬁcantly with HIF-1a expression in human cervical
cancer samples. During multistep cervical carcinogen-
esis, the aberrant expression of HGTD-P protein occurs
in CIN1 and might accumulate in the process of
tumorigenesis. Moreover, HGTD-P expression is corre-
lated with parametrial invasion. These facts suggest
that HGTD-P plays an important role in cervical
carcinogenesis. Moreover, HGTD-P can be considered
a valuable tumour marker of cervical neoplasia.
However, the molecular mechanism of HGTD-P
involvement in tumour development and progression
in UCC remains to be elucidated.
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Mutational analysis of E-cadherin, b-catenin
and APC genes in synovial sarcomas
DOI: 10.1111/j.1365-2559.2010.03626.x
Sir: Synovial sarcomas (SSs) are known to have two
major forms, the monophasic ﬁbrous type (MFSS)
composed of spindle cells, and the biphasic type (BSS),
comprising both epithelial cells and spindle cells. The
epithelial cells express E-cadherin and catenins (a, b
and c), whereas the spindle cells react to N-cadherin
and focally to vimentin.
1 E-cadherin inactivation by
mutations
2 and ⁄ or promoter hypermethylation
3 as
well as Snail overexpression observed in MFSSs have
suggested a possible role for epithelial–mesenchymal
transition (EMT).
3 In addition, deregulated wingless
(Wnt) activity, demonstrated by frequent nuclear
b-catenin expression associated with less frequent
b-catenin
1,4 and APC mutations,
5 has also been
detected in MFSS. In this study, we screened frozen
tumour samples of 16 (four BSSs and 12 MFSSs)
genetically well-characterized of SSs for mutations of
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